Objective To evaluate the performance of the QStatin scores for predicting the 5-year risk of developing acute renal failure, cataract, liver dysfunction and myopathy in men and women in England and Wales receiving statins. Design Prospective cohort study to evaluate the performance of four statin risk prediction models. Setting 364 practices in the UK contributing to The Health Improvement Network database. Participants 2.2 million patients aged 35–84 years registered with a general practice surgery between 1 January 2002 and 30 June 2008, with 2037 incident cases of acute renal failure, 25 692 incident cataract cases, 14 756 cases of liver dysfunction and 1209 incident cases of myopathy. Main outcome measures First recorded occurrence of acute renal failure, cataract, moderate or severe liver dysfunction and moderate or severe myopathic events as recorded in general practice records. Results Results from this independent and external validation of QStatin scores indicate that models predicting the 5-year statin risk of developing acute renal failure, cataracts and myopathy perform well with areas under the receiver operating characteristic curve ranging from 0.73 to 0.87. Calibration plots for the three models also indicated close agreement between observed and predicted risks. Poor performance was observed for the model predicting the 5-year statin risk of developing liver dysfunction with areas under the receiver operating characteristic curve of 0.64 and 0.60 for women and men, respectively. Conclusions QStatin scores for predicting the 5-year statin risk of developing acute renal failure, cataract and myopathy appear to be useful models with good discriminative and calibration properties. The model for predicting the 5-year statin risk of developing liver dysfunction appears to have limited ability to identify high-risk individuals and the authors caution against its use.
[1]
Ronald Klein,et al.
Statin use and incident nuclear cataract.
,
2006,
JAMA.
[2]
Patrick Royston,et al.
Explained Variation for Survival Models
,
2006
.
[3]
M. Linton,et al.
Current perspectives on statins.
,
2000,
Circulation.
[4]
M. Wallander,et al.
The safety of rosuvastatin in comparison with other statins in over 100 000 statin users in UK primary care
,
2008,
Pharmacoepidemiology and drug safety.
[5]
Yvonne Vergouwe,et al.
Development and validation of a prediction model with missing predictor data: a practical approach.
,
2010,
Journal of clinical epidemiology.
[6]
Carol Coupland,et al.
Individualising the risks of statins in men and women in England and Wales: population-based cohort study
,
2010,
Heart.
[7]
P. Thompson,et al.
Statin-associated myopathy.
,
2003,
JAMA.
[8]
I. Hamilton-Craig,et al.
Statin‐associated myopathy
,
2001,
The Medical journal of Australia.
[9]
R Core Team,et al.
R: A language and environment for statistical computing.
,
2014
.
[10]
J. Schafer.
Multiple imputation: a primer
,
1999,
Statistical methods in medical research.
[11]
E Graf,et al.
Assessment and comparison of prognostic classification schemes for survival data.
,
1999,
Statistics in medicine.
[12]
J. Robson,et al.
Lipid modification: cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease
,
2007,
Heart.
[13]
Patrick Royston,et al.
A new measure of prognostic separation in survival data
,
2004,
Statistics in medicine.